Short-Interval, Low-Dose [177Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma

Stuart More, Thurandie Naiker, Nihaad Jacobs, Ferdinand Oompie, Vikas Prasad

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Prostate-specific membrane antigen (PSMA) is expressed on the neovasculature as well as to some extent on the glioblastoma cells. With this background, we report the case of a 34-year-old man with recurrent glioblastoma who was treated with 2 cycles of low-dose [177Lu]Lu-PSMA after exhausting all available treatment options in the state sector. Baseline imaging demonstrated intense PSMA signal in the known lesion, which was amenable to therapy. The prospect of [177Lu]Lu-PSMA-based therapy for glioblastoma is warranted going forward.

Original languageEnglish
Pages (from-to)E217-E218
JournalClinical nuclear medicine
Issue number5
StatePublished - May 1 2023


  • PET
  • PSMA
  • glioblastoma
  • therapy


Dive into the research topics of 'Short-Interval, Low-Dose [177Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma'. Together they form a unique fingerprint.

Cite this